Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2012, 13(10), 12519-12532; doi:10.3390/ijms131012519
Article

Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells

1
, 1
, 1
, 2
 and 1,*
Received: 26 July 2012; in revised form: 18 September 2012 / Accepted: 21 September 2012 / Published: 28 September 2012
(This article belongs to the Special Issue Advances in Molecular Oncology)
View Full-Text   |   Download PDF [966 KB, uploaded 19 June 2014]
Abstract: The risk of prostate cancer has been increasing in men by degrees. To develop a new prostate cancer therapy, we used a stem cell-derived gene directed prodrug enzyme system using human neural stem cells (hNSCs) that have a tumor-tropic effect. These hNSCs were transduced with the therapeutic genes for bacterial cytosine deaminase (CD), alone or in combination with the one encoding human interferon-beta (IFN-β) or rabbit carboxyl esterase (CE) to generate HB1.F3.CD, HB1.F3.CD.IFN-β, and HB1.F3.CE cells, respectively. CD enzyme can convert the prodrug 5-fluorocytosine (5-FC) into the activated form 5-fluorouracil (5-FU). In addition, CE enzyme can convert the prodrug CPT-11 into a toxic agent, SN-38. In our study, the human stem cells were found to migrate toward LNCaP human prostate cancer cells rather than primary cells. This phenomenon may be due to interactions between chemoattractant ligands and receptors, such as VEGF/VEGFR2 and SCF/c-Kit, expressed as cancer and stem cells, respectively. The HB1.F3.CE, HB.F3.CD, or HB1.F3.CD.IFN-β cells significantly reduced the LNCaP cell viability in the presence of the prodrugs 5-FC or CPT-11. These results indicate that stem cells expressing therapeutic genes can be used to develop a new strategy for selectively treating human prostate cancer.
Keywords: human stem cells; prostate cancer; cytosine deaminase; interferon-beta; carboxyl esterase; tumor-tropism human stem cells; prostate cancer; cytosine deaminase; interferon-beta; carboxyl esterase; tumor-tropism
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Yi, B.-R.; Hwang, K.-A.; Kim, Y.-B.; Kim, S.U.; Choi, K.-C. Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells. Int. J. Mol. Sci. 2012, 13, 12519-12532.

AMA Style

Yi B-R, Hwang K-A, Kim Y-B, Kim SU, Choi K-C. Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells. International Journal of Molecular Sciences. 2012; 13(10):12519-12532.

Chicago/Turabian Style

Yi, Bo-Rim; Hwang, Kyung-A.; Kim, Yun-Bae; Kim, Seung U.; Choi, Kyung-Chul. 2012. "Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells." Int. J. Mol. Sci. 13, no. 10: 12519-12532.



Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert